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cedex 09, France TGFBR1 and TGFBR2 mutations asso-
ciated with Marfan syndrome-related diseases have been
recently suspected to play a key role in triggering the
immune changes responsible for allergic diseases. In this
respect, patients suffering from Marfan and Loeys-Dietz
syndromes exhibited higher rates of (food) allergies, com-
pared to other allergic patients. A possible common
mechanism underlying both disorders should consist of
the altered ability of TGBR1 and TGFBR2 receptors to
properly respond to the recognition of the TGFb signal,
thus preventing the TGFb−signaling pathway from operat-
ing correctly. To check such a hypothesis, we performed
an in silico analysis to predict the effects of point muta-
tions in TGFBR1 and TGFBR2 receptors associated to the
Marfan and Loeys-Dietz syndromes, on the kniase activity
of the serine-kinase domain of both receptors. The most
frequently observed disease-related point mutations in
TGFBR1 and TGFBR2 receptors essentially occur at hot
spots that are located in the surrounding vicinity of the
catalytic loop of the kinase domain. They are susceptible
to modify the local conformation of the catalytic loop and
thus to alter the phosphorylative activity of the kinase
domain for the corresponding substrates, e.g. the SMAD
proteins. Additionally, another point mutation associated
to the Loeys-Dietz disease should modify the local confor-
mation close to the P glycin-rich loop of the kinase
domain, involved in the anchorage of an ATP molecule
which serves as a phosphate-group donor necessary for
the phosphorylation process of the substrate. This point
mutation should also prevent a correct operation for
the kinase domain of the TGFb receptors. Although
they remain speculative, our modeling results bring some
credit to the hypothesis that selected point mutations
occurring at hot spots in both TGFBR1 and TGFBR2
kinase domains, consist of a possible driven mechanism in
promoting allergic disorders via an alteration of the phos-
phorylation capacity of the kinase domain of the TGFb
receptors. Obviously, these predictions need to be substan-
ciated by experimental results.
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